We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Pfizer
PFE
$153B
| $5.07M | 0.01% |
+123,458
| New | +$4.9M |
|
377
H&R Block
HRB
$5.86B
| $4.89M | 0.01% |
166,796
+64,759
| +63% | +$1.74M |
|
378
Alerian MLP ETF
AMLP
$12.8B
| $4.86M | 0.01% |
98,766
-6,550
| -6% | -$324K |
|
379
Home Depot
HD
$355B
| $4.86M | 0.01% |
23,364
+6,707
| +40% | +$1.34M |
|
|
CPLG
380
DELISTED
CorePoint Lodging Inc. Common Stock
CPLG
| $4.79M | 0.01% |
386,325
-6,592
| -2% | -$83.5K |
|
381
Omnicom Group
OMC
$23.4B
| $4.78M | 0.01% |
58,292
-7,941
| -12% | -$627K |
|
382
Cummins
CMI
$88.7B
| $4.77M | 0.01% |
27,838
-4,560
| -14% | -$747K |
|
383
Citigroup
C
$226B
| $4.68M | 0.01% |
66,866
-11,154
| -14% | -$746K |
|
384
PACCAR
PCAR
$70.1B
| $4.68M | 0.01% |
98,012
-13,951
| -12% | -$648K |
|
385
Leidos
LDOS
$17.3B
| $4.67M | 0.01% |
58,418
+48,842
| +510% | +$3.57M |
|
386
Hewlett Packard
HPE
$70.5B
| $4.64M | 0.01% |
310,474
+160,086
| +106% | +$2.43M |
|
387
Eaton
ETN
$174B
| $4.64M | 0.01% |
55,663
-6,636
| -11% | -$537K |
|
388
Gilead Sciences
GILD
$165B
| $4.63M | 0.01% |
68,541
+22,721
| +50% | +$1.49M |
|
389
Las Vegas Sands
LVS
$29.6B
| $4.63M | 0.01% |
+78,313
| New | +$4.85M |
|
390
HP
HPQ
$27.5B
| $4.61M | 0.01% |
221,627
-12,548
| -5% | -$248K |
|
391
Johnson & Johnson
JNJ
$625B
| $4.6M | 0.01% |
33,037
-3,471
| -10% | -$480K |
|
|
AGN
392
DELISTED
Allergan plc
AGN
| $4.57M | 0.01% |
27,314
-5,914
| -18% | -$819K |
|
393
MetLife
MET
$62.1B
| $4.56M | 0.01% |
91,838
+29,373
| +47% | +$1.38M |
|
394
Mastercard
MA
$493B
| $4.54M | 0.01% |
17,163
-4,999
| -23% | -$1.25M |
|
395
AngioDynamics
ANGO
$649M
| $4.53M | 0.01% |
229,964
+63,027
| +38% | +$1.28M |
|
396
Cencora
COR
$61.2B
| $4.52M | 0.01% |
53,031
-7,818
| -13% | -$618K |
|
397
Boeing
BA
$185B
| $4.52M | 0.01% |
12,406
+2,744
| +28% | +$1M |
|
398
Broadcom
AVGO
$2.04T
| $4.49M | 0.01% |
155,840
-20,880
| -12% | -$608K |
|
399
Illinois Tool Works
ITW
$84.5B
| $4.39M | 0.01% |
29,122
-3,126
| -10% | -$472K |
|
400
ConocoPhillips
COP
$141B
| $4.38M | 0.01% |
71,797
+71,719
| +91,947% | +$4.46M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.